Question of the Week - January 30th
Ertugliflozin (Steglatro) is a newly approved SGLT-2 Inhibitor. Teaching points for patients include which of the following?
0 points
Submit
This form was created inside of Diabetes Educational Services. Report Abuse - Terms of Service - Additional Terms